Phase 3 Clinical Trials With Primary Completion Dates in February 2023

This is a list of Phase 3 trials with primary completion dates in February 2023 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
ALID Allied Corp. 2023-02-01 Phase 3 NCT04750070 Management of Shock in Children With SAM or Severe Underweight and Diarrhea
ALVO Alvotech 2023-02-01 Phase 3 NCT05155293 Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE)
BTAI BioXcel Therapeutics, Inc. 2023-02-01 Phase 3 NCT05271552 Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)
CERE Cerevel Therapeutics Holdings, Inc. 2023-02-01 Phase 3 NCT04542499 Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations
CSTL Castle Biosciences, Inc. 2023-02-01 Phase 3 NCT04213261 A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa
CYDY CytoDyn Inc. 2023-02-01 Phase 3 NCT04901689 Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation
JAZZ Jazz Pharmaceuticals plc 2023-02-01 Phase 3 NCT04203498 Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis
MGCLF MGC Pharmaceuticals Limited 2023-02-01 Phase 3 NCT04802382 Clinical Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19
TVTX Travere Therapeutics, Inc. 2023-02-01 Phase 3 NCT03493685 Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
URGN UroGen Pharma Ltd. 2023-02-01 Phase 3 NCT05243550 A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer